EyePoint Pharmaceuticals, Inc. – NASDAQ:EYPT
EyePoint Pharmaceuticals stock price today
$11.04
+3.83
+53.33%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
EyePoint Pharmaceuticals stock price monthly change
-30.30%
month
EyePoint Pharmaceuticals stock price quarterly change
-30.30%
quarter
EyePoint Pharmaceuticals stock price yearly change
-70.16%
year
EyePoint Pharmaceuticals key metrics
Market Cap | 494.81M |
Enterprise value | 77.59M |
P/E | -1.15 |
EV/Sales | 1.87 |
EV/EBITDA | -0.80 |
Price/Sales | 3.06 |
Price/Book | 1.31 |
PEG ratio | 0.03 |
EPS | -1.82 |
Revenue | 50.01M |
EBITDA | -83.01M |
Income | -78.91M |
Revenue Q/Q | 52.07% |
Revenue Y/Y | 25.69% |
Profit margin | -246.97% |
Oper. margin | -190.64% |
Gross margin | 79.89% |
EBIT margin | -190.64% |
EBITDA margin | -165.96% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEyePoint Pharmaceuticals stock price history
EyePoint Pharmaceuticals stock forecast
EyePoint Pharmaceuticals financial statements
Average Price Target
$22
Potential upside: 99.27%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 9.10M | -22.92M | -251.73% |
|---|---|---|---|
| Sep 2023 | 15.20M | -12.61M | -82.96% |
| Dec 2023 | 14.02M | -14.09M | -100.51% |
| Mar 2024 | 11.68M | -29.28M | -250.63% |
| Jun 2023 | 175655000 | 118.39M | 67.4% |
|---|---|---|---|
| Sep 2023 | 160043000 | 101.42M | 63.37% |
| Dec 2023 | 355184000 | 88.86M | 25.02% |
| Mar 2024 | 329247000 | 79.31M | 24.09% |
| Jun 2023 | 57.02M | 13.46M | -36.65M |
|---|---|---|---|
| Sep 2023 | -15.20M | -1.72M | 10.36M |
| Dec 2023 | -23.10M | -47.14M | 218.48M |
| Mar 2024 | -31.17M | 20.80M | 115K |
EyePoint Pharmaceuticals alternative data
| Aug 2023 | 144 |
|---|---|
| Sep 2023 | 144 |
| Oct 2023 | 144 |
| Nov 2023 | 144 |
| Dec 2023 | 144 |
| Jan 2024 | 144 |
| Feb 2024 | 144 |
| Mar 2024 | 121 |
| Apr 2024 | 121 |
| May 2024 | 121 |
| Jun 2024 | 121 |
| Jul 2024 | 121 |
EyePoint Pharmaceuticals other data
25.31%
-53.35%
of EYPT is owned by hedge funds
34
-38
9.44M
-19.92M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 0 | 764656 |
| Sep 2023 | 0 | 40000 |
| Dec 2023 | 2507292 | 2097083 |
| Jan 2024 | 855000 | 4018207 |
| Feb 2024 | 0 | 209 |
| Apr 2024 | 581765 | 0 |
| May 2024 | 850000 | 11625 |
| Jun 2024 | 0 | 11625 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | ZADEREJ KAREN L. director | Common Stock | 2,000 | N/A | N/A | ||
Option | ZADEREJ KAREN L. director | Common Stock | 2,000 | N/A | N/A | ||
Option | ZADEREJ KAREN L. director | Restricted Stock Units | 2,000 | N/A | N/A | ||
Option | ZADEREJ KAREN L. director | Restricted Stock Units | 2,000 | N/A | N/A | ||
Option | DUKER JAY S. director, officer.. | Common Stock | 16,666 | N/A | N/A | ||
Option | DUKER JAY S. director, officer.. | Restricted Stock Units | 16,666 | N/A | N/A | ||
Option | LURKER NANCY director, officer.. | Common Stock | 11,111 | N/A | N/A | ||
Option | LURKER NANCY director, officer.. | Restricted Stock Units | 11,111 | N/A | N/A | ||
Option | ADAMIS ANTHONY P director | Restricted Stock Units | 2,000 | N/A | N/A | ||
Option | ADAMIS ANTHONY P director | Common Stock | 2,000 | N/A | N/A |
| Quarter | Transcript |
|---|---|
| Q4 2023 7 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 1 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q1 2023 3 May 2023 | Q1 2023 Earnings Call Transcript |
Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy
EyePoint: A Risky 'Buy' Ahead Of Key Readout For Long-Acting Eylea Rival
EyePoint Stock: NPDR Endpoint Miss Is A Buying Opportunity Based On Lead Program
EyePoint: Well-Funded And Catalyst-Rich, But Not Without Risks
EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug Success
Next Round Of Financing Will Be Transformational For Ocular Therapeutix
EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development
-
What's the price of EyePoint Pharmaceuticals stock today?
One share of EyePoint Pharmaceuticals stock can currently be purchased for approximately $11.04.
-
When is EyePoint Pharmaceuticals's next earnings date?
Unfortunately, EyePoint Pharmaceuticals's (EYPT) next earnings date is currently unknown.
-
Does EyePoint Pharmaceuticals pay dividends?
No, EyePoint Pharmaceuticals does not pay dividends.
-
How much money does EyePoint Pharmaceuticals make?
EyePoint Pharmaceuticals has a market capitalization of 494.81M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 11.14% to 46.02M US dollars.
-
What is EyePoint Pharmaceuticals's stock symbol?
EyePoint Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "EYPT".
-
What is EyePoint Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of EyePoint Pharmaceuticals?
Shares of EyePoint Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are EyePoint Pharmaceuticals's key executives?
EyePoint Pharmaceuticals's management team includes the following people:
- Ms. Nancy S. Lurker Pres, Chief Executive Officer & Director(age: 68, pay: $1,050,000)
- Dr. Dario A. Paggiarino Senior Vice President & Chief Medical Officer(age: 68, pay: $694,190)
- Mr. George O. Elston Chief Financial Officer & Head of Corporation Devel.(age: 60, pay: $692,600)
- Mr. David Scott Jones Senior Vice President & Chief Commercial Officer(age: 58, pay: $604,040)
- Dr. Jay S. Duker M.D. Chief Operating Officer(age: 66, pay: $28,230)
-
How many employees does EyePoint Pharmaceuticals have?
As Jul 2024, EyePoint Pharmaceuticals employs 121 workers.
-
When EyePoint Pharmaceuticals went public?
EyePoint Pharmaceuticals, Inc. is publicly traded company for more then 20 years since IPO on 27 Jan 2005.
-
What is EyePoint Pharmaceuticals's official website?
The official website for EyePoint Pharmaceuticals is eyepointpharma.com.
-
Where are EyePoint Pharmaceuticals's headquarters?
EyePoint Pharmaceuticals is headquartered at 480 Pleasant Street, Watertown, MA.
-
How can i contact EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals's mailing address is 480 Pleasant Street, Watertown, MA and company can be reached via phone at +61 79265000.
-
What is EyePoint Pharmaceuticals stock forecast & price target?
Based on 1 Wall Street analysts` predicted price targets for EyePoint Pharmaceuticals in the last 12 months, the avarage price target is $22. The average price target represents a 99.27% change from the last price of $11.04.
EyePoint Pharmaceuticals company profile:
EyePoint Pharmaceuticals, Inc.
eyepointpharma.comExchange:
NASDAQ
Full time employees:
121
Industry:
Biotechnology
Sector:
Healthcare
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
480 Pleasant Street
Watertown, MA 02472
Watertown, MA 02472
CIK: 0001314102
ISIN: US30233G2093
CUSIP: 30233G209
